Publications dans lesquelles il/elle collabore avec Laura Izquierdo Sánchez (23)

2024

  1. Comparing Survival of Perihilar Cholangiocarcinoma After R1 Resection Versus Palliative Chemotherapy for Unresected Localized Disease

    Annals of Surgical Oncology, Vol. 31, Núm. 10, pp. 6495-6503

2023

  1. A second update on mapping the human genetic architecture of COVID-19

    Nature

  2. A3907, a systemic ASBT inhibitor, improves cholestasis in mice by multiorgan activity and shows translational relevance to humans

    Hepatology (Baltimore, Md.), Vol. 78, Núm. 3, pp. 709-726

  3. Cirrhosis is associated with lower serological responses to COVID-19 vaccines in patients with chronic liver disease

    JHEP Reports, Vol. 5, Núm. 5

  4. Erratum to: Mapping the human genetic architecture of COVID-19 (Nature, (2021), 600, 7889, (472-477), 10.1038/s41586-021-03767-x)

    Nature

  5. Liquid biopsy-based protein biomarkers for risk prediction, early diagnosis, and prognostication of cholangiocarcinoma

    Journal of Hepatology, Vol. 79, Núm. 1, pp. 93-108

  6. Metabolic liver cancer: associations of rare and common germline variants in one-carbon metabolism and DNA methylation genes

    Human molecular genetics, Vol. 32, Núm. 16, pp. 2646-2655

  7. miR-21-5p promotes NASH-related hepatocarcinogenesis

    Liver International, Vol. 43, Núm. 10, pp. 2256-2274

2022

  1. Association between Metabolic Disorders and Cholangiocarcinoma: Impact of a Postulated Risk Factor with Rising Incidence

    Cancers, Vol. 14, Núm. 14

  2. Cholangiocarcinoma landscape in Europe: Diagnostic, prognostic and therapeutic insights from the ENSCCA Registry

    Journal of Hepatology, Vol. 76, Núm. 5, pp. 1109-1121

  3. Detailed stratified GWAS analysis for severe COVID-19 in four European populations

    Human Molecular Genetics, Vol. 31, Núm. 23, pp. 3945-3966

  4. Genetics, pathobiology and therapeutic opportunities of polycystic liver disease

    Nature Reviews Gastroenterology and Hepatology, Vol. 19, Núm. 9, pp. 585-604

  5. Impact of Positive Lymph Nodes and Resection Margin Status on the Overall Survival of Patients with Resected Perihilar Cholangiocarcinoma: The ENSCCA Registry

    Cancers, Vol. 14, Núm. 10

  6. Metabolic subtypes of patients with NAFLD exhibit distinctive cardiovascular risk profiles

    Hepatology, Vol. 76, Núm. 4, pp. 1121-1134

2021

  1. A look back at cholangiocarcinoma in Finland

    United European Gastroenterology Journal

  2. Inhibition of NAE-dependent protein hyper-NEDDylation in cystic cholangiocytes halts cystogenesis in experimental models of polycystic liver disease

    United European Gastroenterology Journal, Vol. 9, Núm. 7, pp. 848-859

  3. Mapping the human genetic architecture of COVID-19

    Nature, Vol. 600, Núm. 7889, pp. 472-477

  4. Synthetic Conjugates of Ursodeoxycholic Acid Inhibit Cystogenesis in Experimental Models of Polycystic Liver Disease

    Hepatology, Vol. 73, Núm. 1, pp. 186-203

  5. Targeting UBC9-mediated protein hyper-SUMOylation in cystic cholangiocytes halts polycystic liver disease in experimental models

    Journal of Hepatology, Vol. 74, Núm. 2, pp. 394-406

2020

  1. Genomewide association study of severe covid-19 with respiratory failure

    New England Journal of Medicine, Vol. 383, Núm. 16, pp. 1522-1534